$太平洋生物科学(PACB)$ $Illumina(ILMN)$ 
节选一下Illumina的CEO Francis deSouza在Goldman Sachs Healthcare Conference上有关PACB的言论：
“Yes, so we announced in the fall of last year that we were acquiring PacBio, PacBio provide sequencers in the long read market. So that's about 5% of the overall sequencing market that we actually don't serve today. And it’s a segment of the market where customers will want to sequence for example a new species where there isn't a reference genome or they'll want to or applications like organ transplant, they want to read parts of the genome for example where it's hard to read using short read technology.We play in different parts of the market. You wouldn't use a long read sequencer for example in markets like NIPT where you're reading 160 base fragments reading it 10,000 it doesn't make sense for those markets, it's a higher cost per sequencing to do the long read sequencing.
But in those markets where you want that data that's what you'll do. So we announced last year that we are looking to acquire PacBio. That acquisition will require approval both in the U.S. and in the U.K. and we're in process with both the FTC here in the U.S. and the CMA. We said we expect that acquisition to close mid-year and that we're expecting to hear back from both the CMA and the U.K. and the FTC in the U.S.
In the U.S., the decision will be made by the five commissioners of the FTC and in the CMA, we'll be hearing about they’re in the first phase of review and the choices are they can approve it, reject it or they can move into a second phase of review. And so we don't really have new news around that, we're still in that process.”
总而言之，收购的成功需要美国FTC和英国CMA的同意，两个机构在近期（本年中段）都会给出答复，而CMA除了同意或拒绝之外还可能将审查拖入第二阶段。CMA的入局确实使局势复杂化了，尤其是市场担心CMA会出于对英国本土企业Oxford Nanopore的保护而妨碍收购的顺利进行，平白增加了不少变数和不确定性。这大概也是最近股价波动下跌的主要原因